Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

December 31, 2020

Primary Completion Date

October 31, 2022

Study Completion Date

June 30, 2024

Conditions

Ankylosing Spondylitis

Interventions

DRUG

Filgotinib

Tablets administered orally once daily

DRUG

Placebo to Match Filgotinib

Tablets administered orally once daily